Crossmark

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Crossref DOI link: https://doi.org/10.1186/s12885-019-5540-5

Published Online: 2019-04-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beukhof, Carolien M. http://orcid.org/0000-0003-3899-4963
Brabander, Tessa

van Nederveen, Francien H.

van Velthuysen, Marie-Louise F.

de Rijke, Yolanda B.

Hofland, Leo J.

Franssen, Gaston J. H.

Fröberg, Lideke A. C.

Kam, Boen L. R.

Visser, W. Edward

de Herder, Wouter W.

Peeters, Robin P.
License Information

Text and Data Mining valid from 2019-04-05
More Information

Article History

Received: 22 January 2019

Accepted: 28 March 2019

First Online: 5 April 2019

Ethics approval and consent to participate

: The study was approved by the Institutional Review Board of the Erasmus Medical Center (127.545/1993/84) and written informed consent was obtained from participants.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.